These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 17920256)
41. A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium. Anzueto A; Niewoehner DE; Leimer I; Rühmkorf F; Celli BR; Decramer M; Tashkin DP Respir Med; 2013 Dec; 107(12):1912-22. PubMed ID: 23969305 [TBL] [Abstract][Full Text] [Related]
42. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Buhl R; Dunn LJ; Disdier C; Lassen C; Amos C; Henley M; Kramer B; Eur Respir J; 2011 Oct; 38(4):797-803. PubMed ID: 21622587 [TBL] [Abstract][Full Text] [Related]
43. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Casaburi R; Kukafka D; Cooper CB; Witek TJ; Kesten S Chest; 2005 Mar; 127(3):809-17. PubMed ID: 15764761 [TBL] [Abstract][Full Text] [Related]
44. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. Vestbo J; Vogelmeier C; Creemers J; Falques M; Ribera A; Gil EG COPD; 2010 Oct; 7(5):331-6. PubMed ID: 20854047 [TBL] [Abstract][Full Text] [Related]
45. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. Tashkin DP; Pearle J; Iezzoni D; Varghese ST COPD; 2009 Feb; 6(1):17-25. PubMed ID: 19229704 [TBL] [Abstract][Full Text] [Related]
46. [The effect of inhaled anticholinergic drugs (tiotropium bromide) on asthma patients with persistent obstructive ventilatory impairment]. Nogami H; Honjo S; Iwanaga T Arerugi; 2012 Nov; 61(11):1675-82. PubMed ID: 23328224 [TBL] [Abstract][Full Text] [Related]
47. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Rossi A; Centanni S; Cerveri I; Gulotta C; Foresi A; Cazzola M; Brusasco V Respir Med; 2012 Jan; 106(1):84-90. PubMed ID: 22035851 [TBL] [Abstract][Full Text] [Related]
48. Tiotropium versus placebo for inadequately controlled asthma: a meta-analysis. Tian JW; Chen JW; Chen R; Chen X Respir Care; 2014 May; 59(5):654-66. PubMed ID: 24170916 [TBL] [Abstract][Full Text] [Related]
49. Concomitant use of ipratropium and tiotropium in chronic obstructive pulmonary disease. Cole JM; Sheehan AH; Jordan JK Ann Pharmacother; 2012 Dec; 46(12):1717-21. PubMed ID: 23170031 [TBL] [Abstract][Full Text] [Related]
50. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Celli B; ZuWallack R; Wang S; Kesten S Chest; 2003 Nov; 124(5):1743-8. PubMed ID: 14605043 [TBL] [Abstract][Full Text] [Related]
51. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. Vogelmeier C; Aquino TO; O'Brien CD; Perrett J; Gunawardena KA COPD; 2012 Apr; 9(2):111-20. PubMed ID: 22458939 [TBL] [Abstract][Full Text] [Related]
52. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Rennard S; Bantje T; Centanni S; Chanez P; Chuchalin A; D'Urzo A; Kornmann O; Perry S; Jack D; Owen R; Higgins M Respir Med; 2008 Jul; 102(7):1033-44. PubMed ID: 18479895 [TBL] [Abstract][Full Text] [Related]
53. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. van Noord JA; Bantje TA; Eland ME; Korducki L; Cornelissen PJ Thorax; 2000 Apr; 55(4):289-94. PubMed ID: 10722768 [TBL] [Abstract][Full Text] [Related]
54. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Jung KS; Park HY; Park SY; Kim SK; Kim YK; Shim JJ; Moon HS; Lee KH; Yoo JH; Lee SD; ; Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275 [TBL] [Abstract][Full Text] [Related]
55. Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD. Ichinose M; Seyama K; Nishimura M; Fukuchi Y; Nagai A; Mishima M; Kubo K; Respir Med; 2010 Feb; 104(2):267-74. PubMed ID: 19875277 [TBL] [Abstract][Full Text] [Related]
56. Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. Cooper CB; Anzueto A; Decramer M; Celli B; Tashkin DP; Leimer I; Kesten S Int J Chron Obstruct Pulmon Dis; 2011; 6():269-75. PubMed ID: 21845038 [TBL] [Abstract][Full Text] [Related]
57. Tiotropium Respimat inhaler and the risk of death in COPD. Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P; N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515 [TBL] [Abstract][Full Text] [Related]
58. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Calverley PM; Lee A; Towse L; van Noord J; Witek TJ; Kelsen S Thorax; 2003 Oct; 58(10):855-60. PubMed ID: 14514937 [TBL] [Abstract][Full Text] [Related]
59. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Terzano C; Petroianni A; Conti V; Ceccarelli D; Graziani E; Sanduzzi A; D'Avelli S Respir Med; 2008 Dec; 102(12):1701-7. PubMed ID: 18760583 [TBL] [Abstract][Full Text] [Related]